Q1 EPS Estimates for Astria Therapeutics Cut by Wedbush

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Analysts at Wedbush reduced their Q1 2025 earnings per share estimates for Astria Therapeutics in a report released on Wednesday, March 12th. Wedbush analyst L. Chico now expects that the biotechnology company will post earnings per share of ($0.46) for the quarter, down from their previous estimate of ($0.40). Wedbush has a “Outperform” rating and a $28.00 price objective on the stock. The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share. Wedbush also issued estimates for Astria Therapeutics’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.48) EPS, FY2025 earnings at ($1.88) EPS, FY2026 earnings at ($1.93) EPS, FY2027 earnings at ($2.22) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at $2.40 EPS.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.01.

A number of other research analysts have also recently weighed in on ATXS. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reissued a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Finally, JMP Securities initiated coverage on Astria Therapeutics in a research note on Friday, January 31st. They set an “outperform” rating and a $26.00 target price on the stock. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $26.67.

Astria Therapeutics Stock Down 2.9 %

ATXS stock opened at $6.45 on Friday. Astria Therapeutics has a twelve month low of $5.73 and a twelve month high of $16.90. The stock has a market cap of $364.00 million, a P/E ratio of -3.09 and a beta of 0.69. The business’s 50-day moving average price is $7.14 and its 200-day moving average price is $9.51.

Institutional Trading of Astria Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. purchased a new position in shares of Astria Therapeutics in the 4th quarter worth approximately $25,680,000. FMR LLC boosted its holdings in shares of Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after purchasing an additional 750,000 shares during the period. Redmile Group LLC purchased a new position in shares of Astria Therapeutics in the 3rd quarter worth approximately $3,423,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Astria Therapeutics by 152.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock valued at $3,460,000 after acquiring an additional 189,727 shares during the period. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.